NCT07204158撤回不适用
Clinical Performance Evaluation of a Medical Device Based on Isotonic Seawater and Hyaluronic Acid Used as a Nasal Spray in Children and Adults With Nasal Dryness: a Prospective, Multicentric, Non-randomized Study in Real-life Conditions.
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- YSLab
- 入组人数
- 65
- 试验地点
- 1
- 主要终点
- Improvement of the nasal dryness symptoms
研究概览
简要总结
The purpose of this study is to see whether the nasal spray can help improve hydration of the nasal mucosa, reduce discomfort linked to nasal dryness, and confirm its safety in patients suffering from nasal dryness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male, female over 6 years old.
- •IC2 Rhinoscopy score of at least 6, with a dryness symptom score of at least
- •Have a smartphone that can use MILO application, for any patient that wishes to answer the questionnaires on their phone.
- •Patient and/or parent/legal guardian can understand and comply with protocol requirements and instructions.
- •Patient willing to not change their daily habits including but not limited to Smoking, use of fireplace candles, air conditioning, cold air, medication and dehumidifier.
- •Signed informed consent (by patient and/or parent/legal guardian).
排除标准
- •Patients taking anticoagulants, over-the-counter or prescription systemic/topical corticosteroids, antibiotics, antihistamines, non-steroidal anti-inflammatory drugs (NSAIDs), leukotriene antagonists, topical or systemic decongestants or any treatment for relieve of nasal symptoms (except acetaminophen) in the two weeks prior to Visit 1 and during the study;
- •Patient with known hyper sensibility to the study treatment;
- •Patients using other nasal sprays, nasal pumps, nasal irrigation/washing devices or nasal oils, creams or gels in the two weeks prior to Visit 1 and during the study;
- •Patients with any dermatological, respiratory or medical condition (e.g., asthma, pneumonia, laryngotracheobronchitis, sinusitis, nasal polyposis and chronic sinusitis, urticaria or eczema) that, in the opinion of the principal investigator, could interfere with the interpretation of study results;
- •Patients with a positive medical history of any significant illness in the 2 weeks preceding the study, which, in the opinion of the principal investigator, could interfere with the interpretation of study results;
- •Patients with nasal anatomical anomalies, e.g., severely deviated septum, congenital cleft lip/palate, nasal hemorrhagic diathesis (assessed by principal investigator);
- •Patient that uses cocaine or other inhaled drugs
- •Patients with any clinically significant co-morbid condition that, in the opinion of the principal investigator, could interfere with the interpretation of study results;
- •Enrolled in another clinical trial or being in a period of exclusion from a previous clinical trial;
- •Women of childbearing age (except menopausal, hysterectomized, and sterilized) are not using effective contraception (oral contraceptives, intra-uterine devices, contraceptive implants, or condoms);
- •A person belonging to a population referred to in articles 64 (incapacitated subjects), 66 (pregnant or breastfeeding women), 67 (persons performing mandatory military service, persons deprived of liberty, persons who, due to a judicial decision) and 68 (patients in an emergency) of the MDR 2017/745.
结局指标
主要结局
Improvement of the nasal dryness symptoms
时间窗: From enrollment to the end of treatment at 1 week
The changes between the baseline and day 7 in the rhinoscopy score will be assessed. The rhinoscopy score is constituted by the sum of the following symptom: dryness, atrophy, redness, oedema of the nasal mucosa and crusting. The clinician will assess each symptom on an ordinal scale of 0-4 (0 = none, 1 = mild, 2 = moderate, 3 = strong, 4 = very strong).
次要结局
- Improvement of the total perceive Nasal symptom relief(From enrollment to the end of treatment at 1 week)
- Safety endpoint(From enrollment to the end of treatment at 1 week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In PediatricsRhinitis, Allergic, PerennialNCT00116883GlaxoSmithKline90
已完成
3 期
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and AdultsRhinitis, Allergic, PerennialNCT00116818GlaxoSmithKline90
已完成
不适用
Efficacy of Two Nasal Products Based on Diluted Seawater in the Treatment of Upper Respiratory Infections/ConditionsSinusitisUpper Respiratory InfectionsColdsRhinitisNCT06498843YSLab89
尚未招募
不适用
Effectiveness of nasal prongs in maintaining oxygenation without respiration in patients while giving general anaesthesiaCTRI/2020/03/023753Department of AnaesthesiologyNDMC Medical College and Hindu Rao Hospital60
撤回
1 期
Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of GlioblastomaGliosarcomaAnaplastic GliomasRecurrent GlioblastomaNCT03275558Center Trials & Treatment